We are happy to announce the FDA approval of the first interchangeable Lucentis® Biosimilar for all Lucentis® approved indications. We would like to thank our great #TeamFormycon and our partners Polpharma Biologics and Bioeq AG for their outstanding work and are looking forward to Coherus BioSciences commercializing the biosimilar in the US.
Read more in our Corporate News.
